ERBB2 and cancer: In the subset of HER2-positive patients (n = 62), those patients with >2 GC in all assessed cancer-free LNs had better OS (OS: HR = 0.33, 95% CI 0.12–0.92, P = 0.036; Supplementary Table 2); however, these significant associations were lost in the multivariate analyses (Supplementary Table 3).